GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Net Margin %

AIM ImmunoTech (LTS:0A4Y) Net Margin % : -10,571.43% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. AIM ImmunoTech's Net Income for the three months ended in Sep. 2024 was $-3.70 Mil. AIM ImmunoTech's Revenue for the three months ended in Sep. 2024 was $0.04 Mil. Therefore, AIM ImmunoTech's net margin for the quarter that ended in Sep. 2024 was -10,571.43%.

The historical rank and industry rank for AIM ImmunoTech's Net Margin % or its related term are showing as below:

LTS:0A4Y' s Net Margin % Range Over the Past 10 Years
Min: -14337.62   Med: -8846.12   Max: -1889.93
Current: -12594.21


LTS:0A4Y's Net Margin % is ranked worse than
92.1% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs LTS:0A4Y: -12594.21

AIM ImmunoTech Net Margin % Historical Data

The historical data trend for AIM ImmunoTech's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Net Margin % Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,717.14 -8,834.36 -14,168.15 -13,790.78 -14,337.62

AIM ImmunoTech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16,991.30 -19,347.69 -14,542.50 -3,672.00 -10,571.43

Competitive Comparison of AIM ImmunoTech's Net Margin %

For the Biotechnology subindustry, AIM ImmunoTech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Net Margin % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Net Margin % falls into.



AIM ImmunoTech Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

AIM ImmunoTech's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-28.962/0.202
=-14,337.62 %

AIM ImmunoTech's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-3.7/0.035
=-10,571.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (LTS:0A4Y) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


AIM ImmunoTech Net Margin % Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Headlines

No Headlines